8 Biopharma Trends and Top Startups to Follow in 2017

by Andrii Buvailo, PhD          Biopharma insight / Biopharma Insights

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   14254    Comments 2
Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email

Pharmaceutical industry is rapidly evolving, influenced by emerging novel technologies and recent advances in Life Sciences and Big Data analysis, new government policies and regulations, and a changing market conjuncture.

Let’s review some of the most powerful trends that will dominate the industry in 2017 and promising biopharmaceutical startups riding their waves.

1. Gene editing: CRISPR/Cas9

Being one of the brightest scientific breakthroughs in years, a new targeted genome editing technology based on the CRISPR-Cas9 system, offers a huge promise for the future of medicine.  

CRISPR (clustered regularly interspaced short palindromic repeats) refers to the system consisting of two key molecules: an enzyme Cas9 -- “molecular scissors” able to cut the two strands of DNA at a specific location in the genome; and a piece of pre-designed RNA sequence -- “guiding” RNA (gRNA), within a longer RNA scaffold. The role of the latter is to direct Cas9 “scissors” to the exact location in the DNA of interest and modify it as desired.

While CRISPR technology is still in its infancy with a number of serious issues to be addressed on the way, the discovery of the CRISPR/Cas9 gene editing approach has already transformed the biomedical research field forever. Compared to its “predecessors”, such as zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), the CRISPR-Cas9 system is simpler, preciser, and relatively cheaper, making it an ideal vehicle for “playing with genome”. And it can be done in high-throughput screening formats.

With all the benefits CRISPR technology represents no wonder it has captured the attention of the popular media, the scientific community and top biotech investors. Over the last several years the number of Google search requests and research citations related to CRISPR have skyrocketed almost exponentially.

Some of the most well-established biotech startups in the field of CRISPR include:

Intellia Therapeutics: (IPO in 2016, highest post-money valuation ever for a pre-clinical biotech startup).  Advances programs for in vivo and ex vivo therapies, the latter including HSC transplants and CARTs.

Editas Medicine (IPO in 2016) develops programs to treat eye diseases, uses engineered T-cells (e.g., CARTs) among other technologies.

CRISPR Therapeutics (IPO in 2016) works on a broad range of diseases including blood disorders, congenital heart disease, blindness, and cystic fibrosis.

Eligo Bioscience: The startup’s advanced approach utilizes the idea of delivering CRISPR via phages to attack selectively nocive bacterial strains.

Other emerging players using CRISPR/Cas9 technology include: Exonics Therapeutics (neuromuscular diseases), Agenovir (viral diseases), Poseida Therapeutics (multiple myeloma, prostate cancer and beta-thalassemia), Synthego, eGenesis, and Benchling.

Continue reading

This content available exclusively for BPT Mebmers

Topics: Industry Trends    Biotech Companies   

Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email

You may also be interested to read:

 

Comments:

  • Curtis Sierra 2017-09-25 11:23

    http://www.ilovegrowingmarijuana.com/qleaner/Hi All, I just want to ask if anyone ever tried using medical cannabis as an alternative meds? I have read many articles about medical marijuana and how it can help you in terms of chronic pain, bone injuries, eating disorder/anorexia, anxiety disorders and panic attacks, inflammation, even cancer and a lot more. Like this article about a marijuana strain called Qleaner from:http://www.ilovegrowingmarijuana.com/qleaner/ . Cbd and thc are also new to me and I don't even smoke. If this is true I cant find any solid conclusive evidence that speaks to its efficacy. Any personal experience or testimonial would be highly appreciated. Thanks

    reply
    • BiopharmaTrend 2017-12-11 11:34

      Curtis, in the above article we are outlining the trends as they are, without providing the opinions. The fact is, the area of medical cannabis is a rapidly growing one.

      However, at BiopharmaTrend we are strongly against the widespread adoption of Medical Cannabis as it is now happening. and we believe extra care should be given to the political and regulatory decisions regarding the legalization of such use cases by the public. We believe the level of harm to the public is substantially higher compared to possible benefits arising from the use of medical cannabis.

      reply

Leave a Reply

Your email address will not be published. Required fields are marked *